of rescue inhalers
3 Basic steps to use ProAir RespiClick®1
Make sure the cap is closed before each dose.
Hold the inhaler upright as you open the cap fully.
Open the cap all the way back until you hear a “click.”
Your ProAir RespiClick ® inhaler is now ready to use.
Do not open the cap unless you are taking a dose.
Breathe out through your mouth and push as much air from your lungs as you can.
Be careful not to breathe out into the inhaler mouthpiece.
Put the mouthpiece in your mouth and close your lips around it. Breathe in deeply through your mouth, until your lungs feel completely full of air.
Breathing in deeply through the mouthpiece will deliver the medication to your lungs.
Do not let your lips or fingers block the vent above the mouthpiece.
Hold your breath for about 10 seconds or as long as you comfortably can.
Remove the inhaler from your mouth.
Check the dose counter on the back of the inhaler to make sure you received the dose.
Always close the cap after each inhalation so your inhaler will be ready for your next dose.
If you need another dose close the cap and repeat all of the steps.
ProAir RespiClick® contains a powder and must be kept clean and dry at all times.
ProAir RespiClick® (albuterol sulfate) inhalation powder is indicated in patients ≥4 years of age for the treatment or prevention of bronchospasm with reversible obstructive airway disease and in patients ≥4 years of age for the prevention of exercise-induced bronchospasm.
Important Safety Information
- Contraindications: ProAir RespiClick (albuterol sulfate) inhalation powder is contraindicated in patients with hypersensitivity to albuterol or patients with a severe hypersensitivity to milk proteins. Rare cases of hypersensitivity reactions, including urticaria, angioedema, and rash have been reported after the use of albuterol sulfate. There have been reports of anaphylactic reactions in patients using inhalation therapies containing lactose
- Paradoxical Bronchospasm: ProAir RespiClick can produce paradoxical bronchospasm that may be life-threatening. Discontinue ProAir RespiClick and institute alternative therapy if paradoxical bronchospasm occurs
- Deterioration of Asthma: Need for more doses of ProAir RespiClick than usual may be a marker of acute or chronic deterioration of asthma and requires reevaluation of treatment, such as possible need for anti-inflammatory treatment, e.g., corticosteroids
- Use of Anti-Inflammatory Agents: ProAir RespiClick alone may not be adequate to control asthma in many patients. Early consideration should be given to adding anti-inflammatory agents, e.g., corticosteroids
- Cardiovascular Effects: ProAir RespiClick, like other beta-adrenergic agonists, can produce clinically significant cardiovascular effects in some patients, as measured by heart rate, blood pressure, and/or symptoms. If such effects occur, the drug may need to be discontinued. ProAir RespiClick, like all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension
- Do Not Exceed Recommended Dose: Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma
- Immediate Hypersensitivity Reactions may occur after administration of albuterol sulfate, as demonstrated by rare cases of urticaria, angioedema, rash, bronchospasm, anaphylaxis, and oropharyngeal edema. Hypersensitivity reactions including anaphylaxis, angioedema, pruritus, and rash have been reported with the use of therapies containing lactose, an inactive ingredient in ProAir RespiClick.
- Coexisting Conditions: ProAir RespiClick, like all sympathomimetic amines, should be used with caution in patients with convulsive disorders, hyperthyroidism, or diabetes mellitus; and in patients who are unusually responsive to sympathomimetic amines.
- Hypokalemia: As with other beta-agonists, ProAir RespiClick may produce significant hypokalemia in some patients. The decrease is usually transient, not requiring supplementation
- Most Common Adverse Reactions (≥1% and >placebo) are back pain, pain, gastroenteritis viral, sinus headache, urinary tract infection, nasopharyngitis, oropharyngeal pain and vomiting
- Drug Interactions: Other short-acting sympathomimetic bronchodilators
should not be used concomitantly with ProAir
- Beta-Blockers: Beta-adrenergic-receptor blocking agents not only block the pulmonary effect of beta-agonists, such as ProAir RespiClick, but may produce severe bronchospasm in asthmatic patients. Therefore, patients with asthma should not normally be treated with beta-blockers
- Diuretics: Caution is advised in the coadministration of beta-agonists with non-potassium sparing diuretics (such as loop or thiazide diuretics). Consider monitoring potassium levels
- Digoxin: Carefully evaluate the serum digoxin levels in patients who are currently receiving digoxin and ProAir RespiClick
- Monoamine Oxidase Inhibitors or Tricyclic Antidepressants: ProAir RespiClick should be administered with extreme caution to patients being treated with these agents, or within 2 weeks of discontinuation of these agents, because the action of albuterol on the cardiovascular system may be potentiated. Consider alternative therapy
1.ProAir RespiClick Patient Information Leaflet. Parsippany, NJ: Teva Respiratory, LLC.
2.Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest. 2005;127(1):335-371.
3.ProAir RespiClick Prescribing Information. Parsippany, NJ: Teva Respiratory, LLC.
4.ProAir HFA Prescribing Information. Parsippany, NJ: Teva Respiratory, LLC.